nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C9—Bexarotene—hematologic cancer	0.0341	0.0628	CbGbCtD
Sitaxentan—CYP2C9—Idarubicin—hematologic cancer	0.0282	0.0521	CbGbCtD
Sitaxentan—CYP2C19—Bortezomib—hematologic cancer	0.0251	0.0463	CbGbCtD
Sitaxentan—CYP2C19—Thalidomide—hematologic cancer	0.0219	0.0404	CbGbCtD
Sitaxentan—CYP2C9—Bortezomib—hematologic cancer	0.0209	0.0385	CbGbCtD
Sitaxentan—CYP2C19—Teniposide—hematologic cancer	0.0209	0.0385	CbGbCtD
Sitaxentan—CYP3A4—Bexarotene—hematologic cancer	0.0198	0.0365	CbGbCtD
Sitaxentan—CYP2C19—Ifosfamide—hematologic cancer	0.0193	0.0355	CbGbCtD
Sitaxentan—CYP3A4—Busulfan—hematologic cancer	0.0184	0.034	CbGbCtD
Sitaxentan—CYP3A4—Lomustine—hematologic cancer	0.0184	0.034	CbGbCtD
Sitaxentan—CYP2C19—Imatinib—hematologic cancer	0.0184	0.0339	CbGbCtD
Sitaxentan—CYP2C9—Thalidomide—hematologic cancer	0.0182	0.0336	CbGbCtD
Sitaxentan—CYP2C9—Teniposide—hematologic cancer	0.0174	0.032	CbGbCtD
Sitaxentan—CYP3A4—Thiotepa—hematologic cancer	0.0164	0.0303	CbGbCtD
Sitaxentan—CYP2C9—Ifosfamide—hematologic cancer	0.016	0.0295	CbGbCtD
Sitaxentan—CYP2C9—Imatinib—hematologic cancer	0.0153	0.0282	CbGbCtD
Sitaxentan—CYP2C9—Nilotinib—hematologic cancer	0.0139	0.0256	CbGbCtD
Sitaxentan—CYP3A4—Methoxsalen—hematologic cancer	0.0128	0.0235	CbGbCtD
Sitaxentan—CYP3A4—Bortezomib—hematologic cancer	0.0121	0.0224	CbGbCtD
Sitaxentan—CYP2C19—Prednisone—hematologic cancer	0.0121	0.0224	CbGbCtD
Sitaxentan—CYP3A4—Daunorubicin—hematologic cancer	0.0116	0.0214	CbGbCtD
Sitaxentan—CYP3A4—Cytarabine—hematologic cancer	0.0102	0.0189	CbGbCtD
Sitaxentan—CYP3A4—Teniposide—hematologic cancer	0.0101	0.0186	CbGbCtD
Sitaxentan—CYP3A4—Ifosfamide—hematologic cancer	0.00931	0.0172	CbGbCtD
Sitaxentan—CYP3A4—Imatinib—hematologic cancer	0.00889	0.0164	CbGbCtD
Sitaxentan—CYP3A4—Ruxolitinib—hematologic cancer	0.00838	0.0155	CbGbCtD
Sitaxentan—CYP3A4—Nilotinib—hematologic cancer	0.00808	0.0149	CbGbCtD
Sitaxentan—CYP3A4—Vinorelbine—hematologic cancer	0.00802	0.0148	CbGbCtD
Sitaxentan—CYP2C9—Cisplatin—hematologic cancer	0.00779	0.0144	CbGbCtD
Sitaxentan—CYP2C19—Dexamethasone—hematologic cancer	0.00757	0.014	CbGbCtD
Sitaxentan—CYP3A4—Triamcinolone—hematologic cancer	0.00733	0.0135	CbGbCtD
Sitaxentan—CYP3A4—Dasatinib—hematologic cancer	0.00714	0.0132	CbGbCtD
Sitaxentan—CYP3A4—Mitoxantrone—hematologic cancer	0.00706	0.013	CbGbCtD
Sitaxentan—CYP2C9—Dexamethasone—hematologic cancer	0.00629	0.0116	CbGbCtD
Sitaxentan—CYP3A4—Betamethasone—hematologic cancer	0.00629	0.0116	CbGbCtD
Sitaxentan—CYP3A4—Prednisolone—hematologic cancer	0.00621	0.0114	CbGbCtD
Sitaxentan—CYP3A4—Prednisone—hematologic cancer	0.00586	0.0108	CbGbCtD
Sitaxentan—CYP3A4—Irinotecan—hematologic cancer	0.00556	0.0102	CbGbCtD
Sitaxentan—CYP3A4—Vinblastine—hematologic cancer	0.00494	0.00911	CbGbCtD
Sitaxentan—CYP3A4—Vincristine—hematologic cancer	0.00486	0.00896	CbGbCtD
Sitaxentan—CYP3A4—Etoposide—hematologic cancer	0.00445	0.00821	CbGbCtD
Sitaxentan—CYP3A4—Dexamethasone—hematologic cancer	0.00366	0.00675	CbGbCtD
Sitaxentan—CYP3A4—Doxorubicin—hematologic cancer	0.00304	0.0056	CbGbCtD
Sitaxentan—EDNRB—lung—hematologic cancer	0.000457	0.139	CbGeAlD
Sitaxentan—EDNRB—testis—hematologic cancer	0.000431	0.131	CbGeAlD
Sitaxentan—EDNRA—lung—hematologic cancer	0.000378	0.115	CbGeAlD
Sitaxentan—EDNRA—testis—hematologic cancer	0.000357	0.108	CbGeAlD
Sitaxentan—EDNRB—lymph node—hematologic cancer	0.000313	0.0951	CbGeAlD
Sitaxentan—CYP2C19—hematopoietic system—hematologic cancer	0.000278	0.0845	CbGeAlD
Sitaxentan—EDNRA—lymph node—hematologic cancer	0.000259	0.0786	CbGeAlD
Sitaxentan—CYP2C9—hematopoietic system—hematologic cancer	0.000215	0.0655	CbGeAlD
Sitaxentan—CYP2C19—blood—hematologic cancer	0.000184	0.056	CbGeAlD
Sitaxentan—CYP3A4—hematopoietic system—hematologic cancer	0.000164	0.0499	CbGeAlD
Sitaxentan—CYP2C9—blood—hematologic cancer	0.000143	0.0434	CbGeAlD
Sitaxentan—CYP3A4—blood—hematologic cancer	0.000109	0.0331	CbGeAlD
Sitaxentan—Headache—Irinotecan—hematologic cancer	1.75e-05	4.97e-05	CcSEcCtD
Sitaxentan—Nausea—Ifosfamide—hematologic cancer	1.74e-05	4.96e-05	CcSEcCtD
Sitaxentan—Feeling abnormal—Triamcinolone—hematologic cancer	1.73e-05	4.93e-05	CcSEcCtD
Sitaxentan—Diarrhoea—Cisplatin—hematologic cancer	1.73e-05	4.93e-05	CcSEcCtD
Sitaxentan—Alopecia—Methotrexate—hematologic cancer	1.73e-05	4.91e-05	CcSEcCtD
Sitaxentan—Vomiting—Gemcitabine—hematologic cancer	1.73e-05	4.91e-05	CcSEcCtD
Sitaxentan—Insomnia—Betamethasone—hematologic cancer	1.73e-05	4.91e-05	CcSEcCtD
Sitaxentan—Insomnia—Dexamethasone—hematologic cancer	1.73e-05	4.91e-05	CcSEcCtD
Sitaxentan—Bradycardia—Doxorubicin—hematologic cancer	1.72e-05	4.9e-05	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	1.72e-05	4.9e-05	CcSEcCtD
Sitaxentan—Discomfort—Prednisone—hematologic cancer	1.71e-05	4.87e-05	CcSEcCtD
Sitaxentan—Mental disorder—Methotrexate—hematologic cancer	1.71e-05	4.87e-05	CcSEcCtD
Sitaxentan—Rash—Gemcitabine—hematologic cancer	1.71e-05	4.87e-05	CcSEcCtD
Sitaxentan—Dermatitis—Gemcitabine—hematologic cancer	1.71e-05	4.87e-05	CcSEcCtD
Sitaxentan—Eye disorder—Epirubicin—hematologic cancer	1.71e-05	4.86e-05	CcSEcCtD
Sitaxentan—Hypersensitivity—Etoposide—hematologic cancer	1.71e-05	4.86e-05	CcSEcCtD
Sitaxentan—Tinnitus—Epirubicin—hematologic cancer	1.71e-05	4.85e-05	CcSEcCtD
Sitaxentan—Malnutrition—Methotrexate—hematologic cancer	1.7e-05	4.84e-05	CcSEcCtD
Sitaxentan—Haemoglobin—Doxorubicin—hematologic cancer	1.7e-05	4.84e-05	CcSEcCtD
Sitaxentan—Headache—Gemcitabine—hematologic cancer	1.7e-05	4.84e-05	CcSEcCtD
Sitaxentan—Nausea—Vincristine—hematologic cancer	1.7e-05	4.84e-05	CcSEcCtD
Sitaxentan—Flushing—Epirubicin—hematologic cancer	1.7e-05	4.83e-05	CcSEcCtD
Sitaxentan—Cardiac disorder—Epirubicin—hematologic cancer	1.7e-05	4.83e-05	CcSEcCtD
Sitaxentan—Rhinitis—Doxorubicin—hematologic cancer	1.7e-05	4.83e-05	CcSEcCtD
Sitaxentan—Hepatitis—Doxorubicin—hematologic cancer	1.69e-05	4.82e-05	CcSEcCtD
Sitaxentan—Haemorrhage—Doxorubicin—hematologic cancer	1.69e-05	4.82e-05	CcSEcCtD
Sitaxentan—Hypersensitivity—Prednisolone—hematologic cancer	1.69e-05	4.79e-05	CcSEcCtD
Sitaxentan—Dyspepsia—Dexamethasone—hematologic cancer	1.68e-05	4.78e-05	CcSEcCtD
Sitaxentan—Dyspepsia—Betamethasone—hematologic cancer	1.68e-05	4.78e-05	CcSEcCtD
Sitaxentan—Urinary tract disorder—Doxorubicin—hematologic cancer	1.67e-05	4.76e-05	CcSEcCtD
Sitaxentan—Urticaria—Triamcinolone—hematologic cancer	1.67e-05	4.75e-05	CcSEcCtD
Sitaxentan—Oedema peripheral—Doxorubicin—hematologic cancer	1.67e-05	4.74e-05	CcSEcCtD
Sitaxentan—Asthenia—Etoposide—hematologic cancer	1.66e-05	4.73e-05	CcSEcCtD
Sitaxentan—Body temperature increased—Triamcinolone—hematologic cancer	1.66e-05	4.73e-05	CcSEcCtD
Sitaxentan—Oedema—Prednisone—hematologic cancer	1.66e-05	4.73e-05	CcSEcCtD
Sitaxentan—Angiopathy—Epirubicin—hematologic cancer	1.66e-05	4.72e-05	CcSEcCtD
Sitaxentan—Urethral disorder—Doxorubicin—hematologic cancer	1.66e-05	4.72e-05	CcSEcCtD
Sitaxentan—Decreased appetite—Dexamethasone—hematologic cancer	1.66e-05	4.72e-05	CcSEcCtD
Sitaxentan—Decreased appetite—Betamethasone—hematologic cancer	1.66e-05	4.72e-05	CcSEcCtD
Sitaxentan—Nausea—Mitoxantrone—hematologic cancer	1.66e-05	4.71e-05	CcSEcCtD
Sitaxentan—Nausea—Irinotecan—hematologic cancer	1.66e-05	4.71e-05	CcSEcCtD
Sitaxentan—Immune system disorder—Epirubicin—hematologic cancer	1.65e-05	4.7e-05	CcSEcCtD
Sitaxentan—Infection—Prednisone—hematologic cancer	1.65e-05	4.7e-05	CcSEcCtD
Sitaxentan—Mediastinal disorder—Epirubicin—hematologic cancer	1.65e-05	4.69e-05	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Betamethasone—hematologic cancer	1.65e-05	4.69e-05	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Dexamethasone—hematologic cancer	1.65e-05	4.69e-05	CcSEcCtD
Sitaxentan—Fatigue—Betamethasone—hematologic cancer	1.65e-05	4.68e-05	CcSEcCtD
Sitaxentan—Fatigue—Dexamethasone—hematologic cancer	1.65e-05	4.68e-05	CcSEcCtD
Sitaxentan—Pain—Betamethasone—hematologic cancer	1.63e-05	4.64e-05	CcSEcCtD
Sitaxentan—Pain—Dexamethasone—hematologic cancer	1.63e-05	4.64e-05	CcSEcCtD
Sitaxentan—Visual impairment—Doxorubicin—hematologic cancer	1.63e-05	4.64e-05	CcSEcCtD
Sitaxentan—Nervous system disorder—Prednisone—hematologic cancer	1.63e-05	4.64e-05	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—SLC35B2—hematologic cancer	1.63e-05	0.000158	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GBA—hematologic cancer	1.63e-05	0.000158	CbGpPWpGaD
Sitaxentan—Tachycardia—Prednisone—hematologic cancer	1.62e-05	4.61e-05	CcSEcCtD
Sitaxentan—Alopecia—Epirubicin—hematologic cancer	1.62e-05	4.6e-05	CcSEcCtD
Sitaxentan—Skin disorder—Prednisone—hematologic cancer	1.61e-05	4.59e-05	CcSEcCtD
Sitaxentan—Nausea—Gemcitabine—hematologic cancer	1.61e-05	4.59e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—MAPK14—hematologic cancer	1.61e-05	0.000157	CbGpPWpGaD
Sitaxentan—Vomiting—Cisplatin—hematologic cancer	1.61e-05	4.58e-05	CcSEcCtD
Sitaxentan—Mental disorder—Epirubicin—hematologic cancer	1.6e-05	4.56e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—MTOR—hematologic cancer	1.6e-05	0.000155	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CB—hematologic cancer	1.6e-05	0.000155	CbGpPWpGaD
Sitaxentan—Rash—Cisplatin—hematologic cancer	1.6e-05	4.54e-05	CcSEcCtD
Sitaxentan—Dermatitis—Cisplatin—hematologic cancer	1.59e-05	4.54e-05	CcSEcCtD
Sitaxentan—Malnutrition—Epirubicin—hematologic cancer	1.59e-05	4.53e-05	CcSEcCtD
Sitaxentan—Diarrhoea—Etoposide—hematologic cancer	1.59e-05	4.51e-05	CcSEcCtD
Sitaxentan—Anorexia—Prednisone—hematologic cancer	1.58e-05	4.51e-05	CcSEcCtD
Sitaxentan—Eye disorder—Doxorubicin—hematologic cancer	1.58e-05	4.5e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—ESR1—hematologic cancer	1.58e-05	0.000154	CbGpPWpGaD
Sitaxentan—Ill-defined disorder—Methotrexate—hematologic cancer	1.58e-05	4.49e-05	CcSEcCtD
Sitaxentan—Tinnitus—Doxorubicin—hematologic cancer	1.58e-05	4.49e-05	CcSEcCtD
Sitaxentan—Anaemia—Methotrexate—hematologic cancer	1.57e-05	4.47e-05	CcSEcCtD
Sitaxentan—Feeling abnormal—Dexamethasone—hematologic cancer	1.57e-05	4.47e-05	CcSEcCtD
Sitaxentan—Feeling abnormal—Betamethasone—hematologic cancer	1.57e-05	4.47e-05	CcSEcCtD
Sitaxentan—Cardiac disorder—Doxorubicin—hematologic cancer	1.57e-05	4.47e-05	CcSEcCtD
Sitaxentan—Flushing—Doxorubicin—hematologic cancer	1.57e-05	4.47e-05	CcSEcCtD
Sitaxentan—Tension—Epirubicin—hematologic cancer	1.56e-05	4.45e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—FN1—hematologic cancer	1.56e-05	0.000152	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Triamcinolone—hematologic cancer	1.55e-05	4.41e-05	CcSEcCtD
Sitaxentan—Nervousness—Epirubicin—hematologic cancer	1.55e-05	4.4e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—BAD—hematologic cancer	1.54e-05	0.00015	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NFKBIA—hematologic cancer	1.54e-05	0.00015	CbGpPWpGaD
Sitaxentan—Angiopathy—Doxorubicin—hematologic cancer	1.54e-05	4.37e-05	CcSEcCtD
Sitaxentan—Malaise—Methotrexate—hematologic cancer	1.54e-05	4.37e-05	CcSEcCtD
Sitaxentan—Dizziness—Etoposide—hematologic cancer	1.53e-05	4.36e-05	CcSEcCtD
Sitaxentan—Muscle spasms—Epirubicin—hematologic cancer	1.53e-05	4.36e-05	CcSEcCtD
Sitaxentan—Immune system disorder—Doxorubicin—hematologic cancer	1.53e-05	4.35e-05	CcSEcCtD
Sitaxentan—Vertigo—Methotrexate—hematologic cancer	1.53e-05	4.35e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—NOTCH1—hematologic cancer	1.53e-05	0.000148	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—HRAS—hematologic cancer	1.53e-05	0.000148	CbGpPWpGaD
Sitaxentan—Mediastinal disorder—Doxorubicin—hematologic cancer	1.53e-05	4.34e-05	CcSEcCtD
Sitaxentan—CYP3A4—Metabolism—SMPD3—hematologic cancer	1.52e-05	0.000148	CbGpPWpGaD
Sitaxentan—Leukopenia—Methotrexate—hematologic cancer	1.52e-05	4.33e-05	CcSEcCtD
Sitaxentan—Urticaria—Betamethasone—hematologic cancer	1.52e-05	4.31e-05	CcSEcCtD
Sitaxentan—Urticaria—Dexamethasone—hematologic cancer	1.52e-05	4.31e-05	CcSEcCtD
Sitaxentan—Dizziness—Prednisolone—hematologic cancer	1.51e-05	4.3e-05	CcSEcCtD
Sitaxentan—Asthenia—Triamcinolone—hematologic cancer	1.51e-05	4.29e-05	CcSEcCtD
Sitaxentan—Body temperature increased—Dexamethasone—hematologic cancer	1.51e-05	4.29e-05	CcSEcCtD
Sitaxentan—Body temperature increased—Betamethasone—hematologic cancer	1.51e-05	4.29e-05	CcSEcCtD
Sitaxentan—Nausea—Cisplatin—hematologic cancer	1.5e-05	4.28e-05	CcSEcCtD
Sitaxentan—Insomnia—Prednisone—hematologic cancer	1.5e-05	4.28e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CDKN1B—hematologic cancer	1.5e-05	0.000146	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CD80—hematologic cancer	1.5e-05	0.000145	CbGpPWpGaD
Sitaxentan—Alopecia—Doxorubicin—hematologic cancer	1.5e-05	4.26e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—KIT—hematologic cancer	1.5e-05	0.000145	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CG—hematologic cancer	1.5e-05	0.000145	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—NRAS—hematologic cancer	1.5e-05	0.000145	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—MTAP—hematologic cancer	1.49e-05	0.000145	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—AKT1—hematologic cancer	1.49e-05	0.000144	CbGpPWpGaD
Sitaxentan—Mental disorder—Doxorubicin—hematologic cancer	1.48e-05	4.22e-05	CcSEcCtD
Sitaxentan—Ill-defined disorder—Epirubicin—hematologic cancer	1.48e-05	4.2e-05	CcSEcCtD
Sitaxentan—Vomiting—Etoposide—hematologic cancer	1.47e-05	4.19e-05	CcSEcCtD
Sitaxentan—Malnutrition—Doxorubicin—hematologic cancer	1.47e-05	4.19e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CASP3—hematologic cancer	1.47e-05	0.000143	CbGpPWpGaD
Sitaxentan—Anaemia—Epirubicin—hematologic cancer	1.47e-05	4.19e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—IL2—hematologic cancer	1.47e-05	0.000143	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTPN11—hematologic cancer	1.47e-05	0.000143	CbGpPWpGaD
Sitaxentan—Agitation—Epirubicin—hematologic cancer	1.46e-05	4.16e-05	CcSEcCtD
Sitaxentan—Dyspepsia—Prednisone—hematologic cancer	1.46e-05	4.16e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—IL6—hematologic cancer	1.46e-05	0.000142	CbGpPWpGaD
Sitaxentan—Rash—Etoposide—hematologic cancer	1.46e-05	4.16e-05	CcSEcCtD
Sitaxentan—Dermatitis—Etoposide—hematologic cancer	1.46e-05	4.16e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—FHL2—hematologic cancer	1.46e-05	0.000141	CbGpPWpGaD
Sitaxentan—Headache—Etoposide—hematologic cancer	1.45e-05	4.13e-05	CcSEcCtD
Sitaxentan—Chest pain—Methotrexate—hematologic cancer	1.45e-05	4.12e-05	CcSEcCtD
Sitaxentan—Tension—Doxorubicin—hematologic cancer	1.45e-05	4.11e-05	CcSEcCtD
Sitaxentan—Decreased appetite—Prednisone—hematologic cancer	1.45e-05	4.11e-05	CcSEcCtD
Sitaxentan—Rash—Prednisolone—hematologic cancer	1.44e-05	4.1e-05	CcSEcCtD
Sitaxentan—Dermatitis—Prednisolone—hematologic cancer	1.44e-05	4.1e-05	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.44e-05	4.09e-05	CcSEcCtD
Sitaxentan—Malaise—Epirubicin—hematologic cancer	1.44e-05	4.09e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CCND1—hematologic cancer	1.43e-05	0.000139	CbGpPWpGaD
Sitaxentan—Fatigue—Prednisone—hematologic cancer	1.43e-05	4.08e-05	CcSEcCtD
Sitaxentan—Headache—Prednisolone—hematologic cancer	1.43e-05	4.08e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—MAPK3—hematologic cancer	1.43e-05	0.000139	CbGpPWpGaD
Sitaxentan—Discomfort—Methotrexate—hematologic cancer	1.43e-05	4.07e-05	CcSEcCtD
Sitaxentan—Nervousness—Doxorubicin—hematologic cancer	1.43e-05	4.07e-05	CcSEcCtD
Sitaxentan—Vertigo—Epirubicin—hematologic cancer	1.43e-05	4.07e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—JUN—hematologic cancer	1.43e-05	0.000139	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AGRN—hematologic cancer	1.43e-05	0.000139	CbGpPWpGaD
Sitaxentan—Leukopenia—Epirubicin—hematologic cancer	1.43e-05	4.06e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CREB1—hematologic cancer	1.42e-05	0.000138	CbGpPWpGaD
Sitaxentan—Constipation—Prednisone—hematologic cancer	1.42e-05	4.04e-05	CcSEcCtD
Sitaxentan—Muscle spasms—Doxorubicin—hematologic cancer	1.42e-05	4.03e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—BRAF—hematologic cancer	1.41e-05	0.000136	CbGpPWpGaD
Sitaxentan—Confusional state—Methotrexate—hematologic cancer	1.4e-05	3.98e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CCL2—hematologic cancer	1.39e-05	0.000135	CbGpPWpGaD
Sitaxentan—Dizziness—Triamcinolone—hematologic cancer	1.39e-05	3.96e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—IL6R—hematologic cancer	1.39e-05	0.000135	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CDKN1A—hematologic cancer	1.39e-05	0.000135	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CREBBP—hematologic cancer	1.39e-05	0.000135	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PTEN—hematologic cancer	1.38e-05	0.000134	CbGpPWpGaD
Sitaxentan—Infection—Methotrexate—hematologic cancer	1.38e-05	3.93e-05	CcSEcCtD
Sitaxentan—Nausea—Etoposide—hematologic cancer	1.38e-05	3.92e-05	CcSEcCtD
Sitaxentan—Feeling abnormal—Prednisone—hematologic cancer	1.37e-05	3.9e-05	CcSEcCtD
Sitaxentan—Asthenia—Dexamethasone—hematologic cancer	1.37e-05	3.89e-05	CcSEcCtD
Sitaxentan—Asthenia—Betamethasone—hematologic cancer	1.37e-05	3.89e-05	CcSEcCtD
Sitaxentan—Ill-defined disorder—Doxorubicin—hematologic cancer	1.37e-05	3.89e-05	CcSEcCtD
Sitaxentan—Nervous system disorder—Methotrexate—hematologic cancer	1.36e-05	3.87e-05	CcSEcCtD
Sitaxentan—Anaemia—Doxorubicin—hematologic cancer	1.36e-05	3.87e-05	CcSEcCtD
Sitaxentan—Thrombocytopenia—Methotrexate—hematologic cancer	1.36e-05	3.87e-05	CcSEcCtD
Sitaxentan—Nausea—Prednisolone—hematologic cancer	1.36e-05	3.86e-05	CcSEcCtD
Sitaxentan—Chest pain—Epirubicin—hematologic cancer	1.36e-05	3.86e-05	CcSEcCtD
Sitaxentan—Agitation—Doxorubicin—hematologic cancer	1.35e-05	3.85e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—MAPK8—hematologic cancer	1.35e-05	0.000131	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—IDH2—hematologic cancer	1.35e-05	0.000131	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—HMMR—hematologic cancer	1.35e-05	0.000131	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—AKT1—hematologic cancer	1.35e-05	0.000131	CbGpPWpGaD
Sitaxentan—Skin disorder—Methotrexate—hematologic cancer	1.35e-05	3.84e-05	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.35e-05	3.83e-05	CcSEcCtD
Sitaxentan—Discomfort—Epirubicin—hematologic cancer	1.34e-05	3.81e-05	CcSEcCtD
Sitaxentan—Vomiting—Triamcinolone—hematologic cancer	1.34e-05	3.8e-05	CcSEcCtD
Sitaxentan—CYP3A4—Metabolism—DCK—hematologic cancer	1.33e-05	0.000129	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—B3GAT1—hematologic cancer	1.33e-05	0.000129	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ASNS—hematologic cancer	1.33e-05	0.000129	CbGpPWpGaD
Sitaxentan—Malaise—Doxorubicin—hematologic cancer	1.33e-05	3.78e-05	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—FHL2—hematologic cancer	1.33e-05	0.000129	CbGpPWpGaD
Sitaxentan—Rash—Triamcinolone—hematologic cancer	1.33e-05	3.77e-05	CcSEcCtD
Sitaxentan—Dry mouth—Epirubicin—hematologic cancer	1.33e-05	3.77e-05	CcSEcCtD
Sitaxentan—Dermatitis—Triamcinolone—hematologic cancer	1.33e-05	3.77e-05	CcSEcCtD
Sitaxentan—Vertigo—Doxorubicin—hematologic cancer	1.32e-05	3.77e-05	CcSEcCtD
Sitaxentan—Anorexia—Methotrexate—hematologic cancer	1.32e-05	3.77e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—MAP2K1—hematologic cancer	1.32e-05	0.000128	CbGpPWpGaD
Sitaxentan—Urticaria—Prednisone—hematologic cancer	1.32e-05	3.76e-05	CcSEcCtD
Sitaxentan—Leukopenia—Doxorubicin—hematologic cancer	1.32e-05	3.75e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—EP300—hematologic cancer	1.32e-05	0.000128	CbGpPWpGaD
Sitaxentan—Headache—Triamcinolone—hematologic cancer	1.32e-05	3.75e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CD—hematologic cancer	1.31e-05	0.000128	CbGpPWpGaD
Sitaxentan—Body temperature increased—Prednisone—hematologic cancer	1.31e-05	3.74e-05	CcSEcCtD
Sitaxentan—Confusional state—Epirubicin—hematologic cancer	1.31e-05	3.73e-05	CcSEcCtD
Sitaxentan—Diarrhoea—Dexamethasone—hematologic cancer	1.31e-05	3.71e-05	CcSEcCtD
Sitaxentan—Diarrhoea—Betamethasone—hematologic cancer	1.31e-05	3.71e-05	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CA—hematologic cancer	1.3e-05	0.000126	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AGRN—hematologic cancer	1.3e-05	0.000126	CbGpPWpGaD
Sitaxentan—Oedema—Epirubicin—hematologic cancer	1.3e-05	3.7e-05	CcSEcCtD
Sitaxentan—Hypotension—Methotrexate—hematologic cancer	1.3e-05	3.69e-05	CcSEcCtD
Sitaxentan—Infection—Epirubicin—hematologic cancer	1.29e-05	3.67e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—KRAS—hematologic cancer	1.29e-05	0.000125	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SRC—hematologic cancer	1.28e-05	0.000125	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.28e-05	0.000124	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Epirubicin—hematologic cancer	1.28e-05	3.63e-05	CcSEcCtD
Sitaxentan—Thrombocytopenia—Epirubicin—hematologic cancer	1.27e-05	3.62e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—ARNTL—hematologic cancer	1.27e-05	0.000123	CbGpPWpGaD
Sitaxentan—Tachycardia—Epirubicin—hematologic cancer	1.27e-05	3.61e-05	CcSEcCtD
Sitaxentan—Skin disorder—Epirubicin—hematologic cancer	1.26e-05	3.59e-05	CcSEcCtD
Sitaxentan—CYP3A4—Metabolism—HDC—hematologic cancer	1.26e-05	0.000123	CbGpPWpGaD
Sitaxentan—Dizziness—Betamethasone—hematologic cancer	1.26e-05	3.59e-05	CcSEcCtD
Sitaxentan—Dizziness—Dexamethasone—hematologic cancer	1.26e-05	3.59e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—FGF2—hematologic cancer	1.26e-05	0.000122	CbGpPWpGaD
Sitaxentan—Insomnia—Methotrexate—hematologic cancer	1.26e-05	3.57e-05	CcSEcCtD
Sitaxentan—Chest pain—Doxorubicin—hematologic cancer	1.25e-05	3.57e-05	CcSEcCtD
Sitaxentan—Nausea—Triamcinolone—hematologic cancer	1.25e-05	3.55e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—VEGFA—hematologic cancer	1.25e-05	0.000121	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.25e-05	3.54e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—PIK3R1—hematologic cancer	1.24e-05	0.00012	CbGpPWpGaD
Sitaxentan—Discomfort—Doxorubicin—hematologic cancer	1.24e-05	3.53e-05	CcSEcCtD
Sitaxentan—Anorexia—Epirubicin—hematologic cancer	1.24e-05	3.52e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—ACP5—hematologic cancer	1.24e-05	0.00012	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CA9—hematologic cancer	1.24e-05	0.00012	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—STAT3—hematologic cancer	1.24e-05	0.00012	CbGpPWpGaD
Sitaxentan—Somnolence—Methotrexate—hematologic cancer	1.24e-05	3.51e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—NRAS—hematologic cancer	1.23e-05	0.00012	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—HMMR—hematologic cancer	1.23e-05	0.00012	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—IDH2—hematologic cancer	1.23e-05	0.00012	CbGpPWpGaD
Sitaxentan—Dry mouth—Doxorubicin—hematologic cancer	1.23e-05	3.49e-05	CcSEcCtD
Sitaxentan—Hypersensitivity—Prednisone—hematologic cancer	1.22e-05	3.48e-05	CcSEcCtD
Sitaxentan—Dyspepsia—Methotrexate—hematologic cancer	1.22e-05	3.48e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—NCOR2—hematologic cancer	1.22e-05	0.000119	CbGpPWpGaD
Sitaxentan—Hypotension—Epirubicin—hematologic cancer	1.21e-05	3.46e-05	CcSEcCtD
Sitaxentan—Vomiting—Dexamethasone—hematologic cancer	1.21e-05	3.45e-05	CcSEcCtD
Sitaxentan—Vomiting—Betamethasone—hematologic cancer	1.21e-05	3.45e-05	CcSEcCtD
Sitaxentan—Confusional state—Doxorubicin—hematologic cancer	1.21e-05	3.45e-05	CcSEcCtD
Sitaxentan—Decreased appetite—Methotrexate—hematologic cancer	1.21e-05	3.43e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—JAK2—hematologic cancer	1.21e-05	0.000117	CbGpPWpGaD
Sitaxentan—Rash—Betamethasone—hematologic cancer	1.2e-05	3.42e-05	CcSEcCtD
Sitaxentan—Rash—Dexamethasone—hematologic cancer	1.2e-05	3.42e-05	CcSEcCtD
Sitaxentan—Oedema—Doxorubicin—hematologic cancer	1.2e-05	3.42e-05	CcSEcCtD
Sitaxentan—Dermatitis—Dexamethasone—hematologic cancer	1.2e-05	3.42e-05	CcSEcCtD
Sitaxentan—Dermatitis—Betamethasone—hematologic cancer	1.2e-05	3.42e-05	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.2e-05	3.41e-05	CcSEcCtD
Sitaxentan—Fatigue—Methotrexate—hematologic cancer	1.2e-05	3.41e-05	CcSEcCtD
Sitaxentan—Headache—Dexamethasone—hematologic cancer	1.2e-05	3.4e-05	CcSEcCtD
Sitaxentan—Headache—Betamethasone—hematologic cancer	1.2e-05	3.4e-05	CcSEcCtD
Sitaxentan—Infection—Doxorubicin—hematologic cancer	1.2e-05	3.4e-05	CcSEcCtD
Sitaxentan—Asthenia—Prednisone—hematologic cancer	1.19e-05	3.39e-05	CcSEcCtD
Sitaxentan—Pain—Methotrexate—hematologic cancer	1.19e-05	3.38e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CA—hematologic cancer	1.18e-05	0.000115	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MAPK3—hematologic cancer	1.18e-05	0.000115	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Doxorubicin—hematologic cancer	1.18e-05	3.36e-05	CcSEcCtD
Sitaxentan—Thrombocytopenia—Doxorubicin—hematologic cancer	1.18e-05	3.35e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—MDM2—hematologic cancer	1.18e-05	0.000114	CbGpPWpGaD
Sitaxentan—Insomnia—Epirubicin—hematologic cancer	1.18e-05	3.34e-05	CcSEcCtD
Sitaxentan—Tachycardia—Doxorubicin—hematologic cancer	1.17e-05	3.34e-05	CcSEcCtD
Sitaxentan—Skin disorder—Doxorubicin—hematologic cancer	1.17e-05	3.32e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—IDH1—hematologic cancer	1.16e-05	0.000113	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.16e-05	0.000113	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ARNTL—hematologic cancer	1.16e-05	0.000113	CbGpPWpGaD
Sitaxentan—Somnolence—Epirubicin—hematologic cancer	1.16e-05	3.29e-05	CcSEcCtD
Sitaxentan—CYP3A4—Metabolism—CDA—hematologic cancer	1.15e-05	0.000112	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ABCC3—hematologic cancer	1.15e-05	0.000112	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TXN—hematologic cancer	1.15e-05	0.000112	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTO1—hematologic cancer	1.15e-05	0.000112	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MYC—hematologic cancer	1.15e-05	0.000112	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TGFB1—hematologic cancer	1.15e-05	0.000111	CbGpPWpGaD
Sitaxentan—Anorexia—Doxorubicin—hematologic cancer	1.15e-05	3.26e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—MTOR—hematologic cancer	1.15e-05	0.000111	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CB—hematologic cancer	1.15e-05	0.000111	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Methotrexate—hematologic cancer	1.14e-05	3.26e-05	CcSEcCtD
Sitaxentan—Dyspepsia—Epirubicin—hematologic cancer	1.14e-05	3.25e-05	CcSEcCtD
Sitaxentan—Diarrhoea—Prednisone—hematologic cancer	1.14e-05	3.23e-05	CcSEcCtD
Sitaxentan—Nausea—Betamethasone—hematologic cancer	1.13e-05	3.22e-05	CcSEcCtD
Sitaxentan—Nausea—Dexamethasone—hematologic cancer	1.13e-05	3.22e-05	CcSEcCtD
Sitaxentan—Decreased appetite—Epirubicin—hematologic cancer	1.13e-05	3.21e-05	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—ACP5—hematologic cancer	1.13e-05	0.00011	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CA9—hematologic cancer	1.13e-05	0.00011	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SPHK1—hematologic cancer	1.13e-05	0.000109	CbGpPWpGaD
Sitaxentan—Hypotension—Doxorubicin—hematologic cancer	1.12e-05	3.2e-05	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.12e-05	3.19e-05	CcSEcCtD
Sitaxentan—Fatigue—Epirubicin—hematologic cancer	1.12e-05	3.19e-05	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—NCOR2—hematologic cancer	1.11e-05	0.000108	CbGpPWpGaD
Sitaxentan—Pain—Epirubicin—hematologic cancer	1.11e-05	3.16e-05	CcSEcCtD
Sitaxentan—Constipation—Epirubicin—hematologic cancer	1.11e-05	3.16e-05	CcSEcCtD
Sitaxentan—CYP3A4—Metabolism—PC—hematologic cancer	1.11e-05	0.000108	CbGpPWpGaD
Sitaxentan—Urticaria—Methotrexate—hematologic cancer	1.1e-05	3.14e-05	CcSEcCtD
Sitaxentan—Dizziness—Prednisone—hematologic cancer	1.1e-05	3.13e-05	CcSEcCtD
Sitaxentan—Body temperature increased—Methotrexate—hematologic cancer	1.1e-05	3.12e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—HRAS—hematologic cancer	1.09e-05	0.000106	CbGpPWpGaD
Sitaxentan—Insomnia—Doxorubicin—hematologic cancer	1.09e-05	3.09e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—UGT1A1—hematologic cancer	1.08e-05	0.000105	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDKN1B—hematologic cancer	1.08e-05	0.000104	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GBA—hematologic cancer	1.07e-05	0.000104	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC35B2—hematologic cancer	1.07e-05	0.000104	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Epirubicin—hematologic cancer	1.07e-05	3.05e-05	CcSEcCtD
Sitaxentan—Somnolence—Doxorubicin—hematologic cancer	1.07e-05	3.04e-05	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—AKT1—hematologic cancer	1.06e-05	0.000103	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KRAS—hematologic cancer	1.06e-05	0.000103	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—IDH1—hematologic cancer	1.06e-05	0.000103	CbGpPWpGaD
Sitaxentan—Dyspepsia—Doxorubicin—hematologic cancer	1.06e-05	3.01e-05	CcSEcCtD
Sitaxentan—Vomiting—Prednisone—hematologic cancer	1.06e-05	3.01e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CASP3—hematologic cancer	1.05e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CRABP1—hematologic cancer	1.05e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC22A1—hematologic cancer	1.05e-05	0.000102	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL2—hematologic cancer	1.05e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTO1—hematologic cancer	1.05e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TXN—hematologic cancer	1.05e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ABCC3—hematologic cancer	1.05e-05	0.000102	CbGpPWpGaD
Sitaxentan—Rash—Prednisone—hematologic cancer	1.05e-05	2.98e-05	CcSEcCtD
Sitaxentan—Dermatitis—Prednisone—hematologic cancer	1.05e-05	2.98e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—IL6—hematologic cancer	1.05e-05	0.000102	CbGpPWpGaD
Sitaxentan—Decreased appetite—Doxorubicin—hematologic cancer	1.05e-05	2.97e-05	CcSEcCtD
Sitaxentan—Headache—Prednisone—hematologic cancer	1.04e-05	2.96e-05	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.04e-05	2.95e-05	CcSEcCtD
Sitaxentan—Fatigue—Doxorubicin—hematologic cancer	1.04e-05	2.95e-05	CcSEcCtD
Sitaxentan—Urticaria—Epirubicin—hematologic cancer	1.03e-05	2.94e-05	CcSEcCtD
Sitaxentan—Constipation—Doxorubicin—hematologic cancer	1.03e-05	2.93e-05	CcSEcCtD
Sitaxentan—Pain—Doxorubicin—hematologic cancer	1.03e-05	2.93e-05	CcSEcCtD
Sitaxentan—Body temperature increased—Epirubicin—hematologic cancer	1.03e-05	2.92e-05	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—SPHK1—hematologic cancer	1.03e-05	9.97e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCND1—hematologic cancer	1.03e-05	9.96e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ALOX5—hematologic cancer	1.03e-05	9.95e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—JUN—hematologic cancer	1.02e-05	9.94e-05	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Methotrexate—hematologic cancer	1.02e-05	2.91e-05	CcSEcCtD
Sitaxentan—Asthenia—Methotrexate—hematologic cancer	9.97e-06	2.83e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—NUP98—hematologic cancer	9.93e-06	9.64e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDKN1A—hematologic cancer	9.92e-06	9.63e-05	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Doxorubicin—hematologic cancer	9.91e-06	2.82e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—PTEN—hematologic cancer	9.9e-06	9.61e-05	CbGpPWpGaD
Sitaxentan—Nausea—Prednisone—hematologic cancer	9.87e-06	2.81e-05	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—UGT1A1—hematologic cancer	9.86e-06	9.57e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MTAP—hematologic cancer	9.82e-06	9.53e-05	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CA—hematologic cancer	9.76e-06	9.47e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAPK8—hematologic cancer	9.69e-06	9.4e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AKT1—hematologic cancer	9.66e-06	9.38e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ADCY7—hematologic cancer	9.64e-06	9.36e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NCOA3—hematologic cancer	9.64e-06	9.36e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CRABP1—hematologic cancer	9.6e-06	9.31e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC22A1—hematologic cancer	9.6e-06	9.31e-05	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Epirubicin—hematologic cancer	9.58e-06	2.72e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—NUP214—hematologic cancer	9.57e-06	9.29e-05	CbGpPWpGaD
Sitaxentan—Urticaria—Doxorubicin—hematologic cancer	9.56e-06	2.72e-05	CcSEcCtD
Sitaxentan—Body temperature increased—Doxorubicin—hematologic cancer	9.51e-06	2.7e-05	CcSEcCtD
Sitaxentan—Diarrhoea—Methotrexate—hematologic cancer	9.51e-06	2.7e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	9.48e-06	9.2e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EP300—hematologic cancer	9.44e-06	9.17e-05	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—hematologic cancer	9.44e-06	9.16e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—MTR—hematologic cancer	9.38e-06	9.1e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ABCG2—hematologic cancer	9.38e-06	9.1e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALOX5—hematologic cancer	9.35e-06	9.08e-05	CbGpPWpGaD
Sitaxentan—Asthenia—Epirubicin—hematologic cancer	9.33e-06	2.65e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—ENO2—hematologic cancer	9.2e-06	8.93e-05	CbGpPWpGaD
Sitaxentan—Dizziness—Methotrexate—hematologic cancer	9.19e-06	2.61e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—SRC—hematologic cancer	9.18e-06	8.91e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NUP98—hematologic cancer	9.06e-06	8.79e-05	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HRAS—hematologic cancer	9.03e-06	8.76e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—VEGFA—hematologic cancer	8.94e-06	8.68e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTT1—hematologic cancer	8.92e-06	8.66e-05	CbGpPWpGaD
Sitaxentan—Diarrhoea—Epirubicin—hematologic cancer	8.9e-06	2.53e-05	CcSEcCtD
Sitaxentan—Hypersensitivity—Doxorubicin—hematologic cancer	8.86e-06	2.52e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—STAT3—hematologic cancer	8.86e-06	8.6e-05	CbGpPWpGaD
Sitaxentan—Vomiting—Methotrexate—hematologic cancer	8.83e-06	2.51e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—NRAS—hematologic cancer	8.83e-06	8.57e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ADCY7—hematologic cancer	8.79e-06	8.53e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NCOA3—hematologic cancer	8.79e-06	8.53e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	8.78e-06	8.53e-05	CbGpPWpGaD
Sitaxentan—Rash—Methotrexate—hematologic cancer	8.76e-06	2.49e-05	CcSEcCtD
Sitaxentan—CYP3A4—Metabolism—FHL2—hematologic cancer	8.75e-06	8.5e-05	CbGpPWpGaD
Sitaxentan—Dermatitis—Methotrexate—hematologic cancer	8.75e-06	2.49e-05	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—NUP214—hematologic cancer	8.73e-06	8.47e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SDC1—hematologic cancer	8.72e-06	8.46e-05	CbGpPWpGaD
Sitaxentan—Headache—Methotrexate—hematologic cancer	8.7e-06	2.48e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—IL6—hematologic cancer	8.64e-06	8.39e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	8.64e-06	8.39e-05	CbGpPWpGaD
Sitaxentan—Asthenia—Doxorubicin—hematologic cancer	8.63e-06	2.45e-05	CcSEcCtD
Sitaxentan—Dizziness—Epirubicin—hematologic cancer	8.6e-06	2.45e-05	CcSEcCtD
Sitaxentan—CYP3A4—Metabolism—AGRN—hematologic cancer	8.58e-06	8.33e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—MTR—hematologic cancer	8.55e-06	8.3e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ABCG2—hematologic cancer	8.55e-06	8.3e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAPK3—hematologic cancer	8.46e-06	8.21e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ENO2—hematologic cancer	8.39e-06	8.14e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	8.33e-06	8.08e-05	CbGpPWpGaD
Sitaxentan—Vomiting—Epirubicin—hematologic cancer	8.27e-06	2.35e-05	CcSEcCtD
Sitaxentan—Nausea—Methotrexate—hematologic cancer	8.25e-06	2.35e-05	CcSEcCtD
Sitaxentan—Diarrhoea—Doxorubicin—hematologic cancer	8.23e-06	2.34e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—MYC—hematologic cancer	8.23e-06	7.99e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	8.22e-06	7.98e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TGFB1—hematologic cancer	8.21e-06	7.97e-05	CbGpPWpGaD
Sitaxentan—Rash—Epirubicin—hematologic cancer	8.2e-06	2.33e-05	CcSEcCtD
Sitaxentan—Dermatitis—Epirubicin—hematologic cancer	8.19e-06	2.33e-05	CcSEcCtD
Sitaxentan—Headache—Epirubicin—hematologic cancer	8.15e-06	2.32e-05	CcSEcCtD
Sitaxentan—CYP3A4—Metabolism—IDH2—hematologic cancer	8.14e-06	7.9e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HMMR—hematologic cancer	8.14e-06	7.9e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTT1—hematologic cancer	8.13e-06	7.9e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	8.01e-06	7.77e-05	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AKT1—hematologic cancer	7.97e-06	7.74e-05	CbGpPWpGaD
Sitaxentan—Dizziness—Doxorubicin—hematologic cancer	7.96e-06	2.26e-05	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—SDC1—hematologic cancer	7.95e-06	7.72e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	7.87e-06	7.63e-05	CbGpPWpGaD
Sitaxentan—Nausea—Epirubicin—hematologic cancer	7.72e-06	2.2e-05	CcSEcCtD
Sitaxentan—CYP3A4—Metabolism—ARNTL—hematologic cancer	7.65e-06	7.43e-05	CbGpPWpGaD
Sitaxentan—Vomiting—Doxorubicin—hematologic cancer	7.65e-06	2.18e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—KRAS—hematologic cancer	7.6e-06	7.38e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	7.59e-06	7.37e-05	CbGpPWpGaD
Sitaxentan—Rash—Doxorubicin—hematologic cancer	7.59e-06	2.16e-05	CcSEcCtD
Sitaxentan—Dermatitis—Doxorubicin—hematologic cancer	7.58e-06	2.16e-05	CcSEcCtD
Sitaxentan—Headache—Doxorubicin—hematologic cancer	7.54e-06	2.14e-05	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	7.5e-06	7.28e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CA9—hematologic cancer	7.44e-06	7.22e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ACP5—hematologic cancer	7.44e-06	7.22e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CD44—hematologic cancer	7.41e-06	7.2e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NQO1—hematologic cancer	7.41e-06	7.2e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NCOR2—hematologic cancer	7.35e-06	7.13e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	7.26e-06	7.05e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	7.17e-06	6.96e-05	CbGpPWpGaD
Sitaxentan—Nausea—Doxorubicin—hematologic cancer	7.15e-06	2.03e-05	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—CYCS—hematologic cancer	7.02e-06	6.81e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—IDH1—hematologic cancer	7e-06	6.79e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CA—hematologic cancer	6.99e-06	6.78e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	6.97e-06	6.77e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTO1—hematologic cancer	6.92e-06	6.72e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TXN—hematologic cancer	6.92e-06	6.72e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ABCC3—hematologic cancer	6.92e-06	6.72e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SPHK1—hematologic cancer	6.77e-06	6.57e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CD44—hematologic cancer	6.76e-06	6.56e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NQO1—hematologic cancer	6.76e-06	6.56e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—hematologic cancer	6.76e-06	6.56e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	6.62e-06	6.43e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—UGT1A1—hematologic cancer	6.51e-06	6.31e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HRAS—hematologic cancer	6.46e-06	6.27e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYCS—hematologic cancer	6.4e-06	6.21e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	6.36e-06	6.17e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC22A1—hematologic cancer	6.33e-06	6.14e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CRABP1—hematologic cancer	6.33e-06	6.14e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	6.27e-06	6.09e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL6—hematologic cancer	6.19e-06	6e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTP1—hematologic cancer	6.18e-06	6e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALOX5—hematologic cancer	6.17e-06	5.99e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.98e-06	5.81e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NUP98—hematologic cancer	5.97e-06	5.8e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ABCB1—hematologic cancer	5.85e-06	5.68e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ADCY7—hematologic cancer	5.8e-06	5.63e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NCOA3—hematologic cancer	5.8e-06	5.63e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NUP214—hematologic cancer	5.76e-06	5.59e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.72e-06	5.55e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AKT1—hematologic cancer	5.71e-06	5.54e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTM1—hematologic cancer	5.68e-06	5.52e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NCOR1—hematologic cancer	5.68e-06	5.52e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ABCG2—hematologic cancer	5.64e-06	5.47e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MTR—hematologic cancer	5.64e-06	5.47e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTP1—hematologic cancer	5.64e-06	5.47e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ENO2—hematologic cancer	5.53e-06	5.37e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.46e-06	5.3e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTT1—hematologic cancer	5.36e-06	5.21e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ABCB1—hematologic cancer	5.34e-06	5.18e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SDC1—hematologic cancer	5.24e-06	5.09e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NCOR1—hematologic cancer	5.18e-06	5.03e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTM1—hematologic cancer	5.18e-06	5.03e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—MTHFR—hematologic cancer	5.02e-06	4.87e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—MTHFR—hematologic cancer	4.58e-06	4.44e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CD44—hematologic cancer	4.46e-06	4.33e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NQO1—hematologic cancer	4.46e-06	4.33e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.43e-06	4.3e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CG—hematologic cancer	4.22e-06	4.1e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYCS—hematologic cancer	4.22e-06	4.1e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	4.19e-06	4.07e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.04e-06	3.92e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CREBBP—hematologic cancer	3.91e-06	3.8e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CG—hematologic cancer	3.85e-06	3.73e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.72e-06	3.61e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CD—hematologic cancer	3.71e-06	3.6e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ALB—hematologic cancer	3.66e-06	3.55e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CREBBP—hematologic cancer	3.57e-06	3.46e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.52e-06	3.42e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3R1—hematologic cancer	3.5e-06	3.4e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.42e-06	3.32e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.42e-06	3.32e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CD—hematologic cancer	3.38e-06	3.28e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALB—hematologic cancer	3.34e-06	3.24e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CB—hematologic cancer	3.23e-06	3.14e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3R1—hematologic cancer	3.19e-06	3.1e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MTHFR—hematologic cancer	3.02e-06	2.93e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CB—hematologic cancer	2.95e-06	2.86e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTEN—hematologic cancer	2.79e-06	2.71e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—EP300—hematologic cancer	2.66e-06	2.59e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTEN—hematologic cancer	2.55e-06	2.47e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.54e-06	2.46e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—EP300—hematologic cancer	2.43e-06	2.36e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.35e-06	2.28e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.23e-06	2.17e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALB—hematologic cancer	2.2e-06	2.14e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.11e-06	2.04e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.97e-06	1.91e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.94e-06	1.89e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CA—hematologic cancer	1.8e-06	1.74e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTEN—hematologic cancer	1.68e-06	1.63e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AKT1—hematologic cancer	1.61e-06	1.56e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—EP300—hematologic cancer	1.6e-06	1.56e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AKT1—hematologic cancer	1.47e-06	1.43e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.19e-06	1.15e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—AKT1—hematologic cancer	9.68e-07	9.4e-06	CbGpPWpGaD
